SCHEMBL3650893

SCHEMBL3650893

Cc1cc(Cl)c2cc(NCc3ccccc3)ccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.56
LMNA P02545 7/20 0.53
MAPT P10636 7/20 0.51
HTT P42858 7/20 0.51
KDM4E B2RXH2 5/20 0.51
PLA2G1B P04054 1/20 0.51
ATG4B Q9Y4P1 1/20 0.51
PTPN1 P18031 1/20 0.50
PTPN11 Q06124 1/20 0.50
IP6K1 Q92551 1/20 0.49
NPSR1 Q6W5P4 4/20 0.47
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
GPR55 Q9Y2T6 1/20 0.47
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
GAA P10253 1/20 0.46
POLB P06746 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4748569 0.80 LMNA (0.58) LMNAMAPTNPSR1USP2SMN1; SMN2
SCHEMBL19539195 0.75 HTT (0.59) LMNAMAPTHTTKDM4EPLA2G1B
SCHEMBL3645814 0.73 NPC1 (0.66) MAPTHTTNPSR1USP2SMN1; SMN2
SCHEMBL8356251 0.73 CD38 (0.55) HTTKDM4ESMN1; SMN2KMT2A
SCHEMBL3646897 0.72 MAPT (0.55) LMNAMAPTKDM4EIP6K1SMN1; SMN2
SCHEMBL11511690 0.72 MEN1 (0.60) DHFRMAPTHTTPLA2G1BATG4B
SCHEMBL3058825 0.72 CYP2C19 (0.64) HTTKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL9363750 0.71 MEN1 (0.61) LMNAMAPTHTTKDM4ENPSR1
SCHEMBL5989580 0.71 KMT2A (0.56) LMNAMAPTKDM4ENPSR1USP2
SCHEMBL318704 0.71 MAPT (0.67) LMNAMAPTHTTKDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2182950-B1 USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS HELPERBY THERAPEUTICS LTD (GB) 2017-07-19 EP disclosed
US-8759348-B2 Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms HELPERBY THERAPEUTICS LIMITED (GB) 2014-06-24 US disclosed
US-20100305065-A1 USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS HELPERBY THERAPEUTICS LIMITED (GB) 2010-12-02 US disclosed
CN-101795688-A Use of 4- (pyrrolidin-1-yl) quinoline compounds to kill clinically latent microorganisms HELPERBY THERAPEUTICS LTD 2010-08-04 CN disclosed
EP-2182950-A1 USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS Helperby Therapeutics Limited (GB) 2010-05-12 EP disclosed
WO-2008142384-A1 USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS HELPERBY THERAPEUTICS LIMITED (GB) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305065-A1 USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS ARG1, LPO, CTSL DHFR 317/4885LMNA 654/4885MAPT 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.